Arresto BiosciencesTM is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. Changes in the normal composition of the extracellular matrix of healthy tissues appear to play a role in the etiology of cancer and diseases with a fibrotic contribution such as liver cirrhosis, pulmonary fibrosis and scleroderma. The treatment of cancer and fibrotic diseases pose a huge unmet clinical need. Drugs that interact with components of the extracellular matrix could offer a treatment option for millions of patients worldwide.
|12/31/07||Series A||16M||Vaizra Investments, The Slater Technology Fund||Unknown|